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Objective: To describe the cutaneous manifestations of COVID-19 disease in patients presenting to a tertiary care 
hospital in Pakistan 
Materials and Methods: This descriptive study was carried out at Benazir Bhutto Hospital, Rawalpindi Medical 
University, Rawalpindi from March 2020 till December 2020. A total of 150 patients were screened by senior 
dermatology postgraduate trainees who were deployed for the care of COVID-19 patients. The demographics, 
rash if any along with its complete history and description, and laboratory investigations were noted on a 
preformed proforma. The pictures of the rash were taken after verbal consent of the patient or surrogate. The 
pictures were then discussed with the consultant for appropriate categorization. 
Results: A total of 150 patients with the diagnosis of COVID-19 were screened. The mean age of the subjects was 
51.9 ± 17.2 years. There were 94 (62.7%) males and 56 (37.3%) females. The mean duration of illness at the time of 
screening was 12.5 ± 9.7 days. Only 7 (4.7%) COVID-19 patients showed skin lesions. These included generalized 
bullous pemphigoid-like (1 patient), urticarial lesions (1 patient), vesicular eruption (1 patient), skin necrosis (1 
patient), and maculopapular rash (3 patients). The average duration of illness at the time of dermatological 
manifestation of COVID-19 was 6.31 ± 2.3 days.   
Conclusion: The skin manifestations of COVID-19 patients in our centre in Pakistan are less as compared to 
reports and data from the western world. However, they are in accordance with the data reported from few Asian 
countries. Regardless of this, the type, distribution, and association of skin lesions with COVID-19 appear to be 
universal. This difference in frequency can be attributed to the racial differences or the variety of COVID-19 viral 
strains predominant in different countries. However, further studies are required to prove this association.   
Keywords: COVID-19, Dermatology, Skin Manifestations, Cutaneous Manifestations. 
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Introduction 
In December 2019, the first cases of pneumonia with 
unknown causes were reported in Wuhan, China.1 The 
new pathogen, called SARS-CoV-2, was isolated from 
samples of the lower respiratory tract of infected 
patients, and the resulting disease was called COVID-
19 (Coronavirus Disease 2019).2 SARS-CoV-2 has 
rapidly spread reaching the level of a pandemic 
disease. 
COVID-19 can affect different organ systems, probably 
including the skin. There is a wide variety of 
descriptions of the cutaneous manifestations of 
COVID-19. Twenty percent of patients in an Italian 
medical ward were found to be having cutaneous 
lesions,3 which prompted researchers to look into this 
interesting association. So, authors from a recent 
Italian study have identified 6 main phenotypes: (1) 
urticarial rash, (2) confluent 
erythematous/maculopapular/morbilliform rash, (3) 
papulovesicular exanthem, (4) a chilblain-like acral 
pattern, (5) a livedo reticularis/racemosa-like pattern, 
and (6) a purpuric vasculitic pattern. However, there 
have been reports of other skin manifestations outside 
this classification, including erythema multiforme–
like, pityriasis rosea–like, and Grover disease–like 
manifestations.4 Most of these reports lack clinical 
images, due to safety concerns.5 The cutaneous 
manifestation of COVID-19 is certainly not limited to 
the aforementioned lesion and as the literature of 
COVID-19 is rapidly evolving, we can expect reporting 
of even more variety of skin lesions associated with 
this menace.  
In this regard, the published data from Pakistan is 
scarce. After an exhaustive survey, we only found one 
recent study published from Pakistan which found the 
frequency of cutaneous manifestations associated with 
COVID-19 to be 11 (2.7%) out of 412 patients.6 Thus, 
we attempted to describe skin manifestations of 
COVID-19 in the Pakistani population. This new 
knowledge can be extremely useful to manage 
patients, to recognize patients of COVID-19 who have 
otherwise few typical symptoms, and might provide 
prognostic information related to the national 
population. The recognition of COVID-19 patients 
with the atypical presentation but having skin 
manifestations could also be helpful for 
epidemiological control especially in areas where 
diagnostic tests are scarce like in  Pakistan due to 
financial restraints.7 
For all these reasons, we conducted a dermatological 
case collection survey, to quickly describe the 
cutaneous manifestations of COVID-19 disease and to 
relate them to disease severity at a tertiary care 
hospital in Rawalpindi, Pakistan which has been 
declared a COVID hospital to manage the pandemic. 
Despite safety concerns, our data is supported by 
clinical images keeping in view strict compliance with 
the personal protective measure as per WHO (World 
Health Organization) guidelines. 
 
Materials and Methods 
This descriptive, cross-sectional study was carried out 
at the department of dermatology, Benazir Bhutto 
Hospital, Rawalpindi. Non-probability and purposive 
sampling techniques were used to induct the subjects 
into the study. The study commenced after 
authorization by the ethics committee. All patients, or 
their next of kin, gave informed verbal consent before 
enrollment in the study to use their data and pictures 
in publications. Afterward, senior dermatology 
postgraduate residents who were deputed in COVID-
19 wards at Dermatology Department, Benazir Bhutto 
Hospital, Rawalpindi enrolled 150 patients in the 
study for 9 months from March 2020 till December 
2020. All patients with an eruption of recent onset 
(previous 2 weeks) and no clear explanation, plus 
confirmed COVID-19 status (either with laboratory 
confirmation of SARS-CoV-2 PCR or HRCT findings 
consistent with COVID-19) were included. An online 
training session for residents was conducted by the 
consultant dermatologist of Rawalpindi Medical 
University to familiarize them with various skin 
manifestations of COVID-19. Residents asked and 
examined patients about skin involvement. Pictures 
were taken of any skin implication of COVID-19 and 
forwarded along with full demographic details and 
clinical summary (including current medical treatment 
details) on a performed proforma to the database 
established in the department of dermatology of 
Benazir Bhutto Hospital. The consultant then analyzed 
the lesions and classified them into various cutaneous 
patterns. All patients who did not have any skin 
manifestation were also reported similarly. Analysis 
was done using SPSS v.23. 
 
Results 
A total of 150 patients presenting to Benazir Bhutto 
Hospital with the diagnosis of COVID-19 were 
screened. The mean age of the subjects was 51.9 ± 17.2 
years. There were 94 (62.7%) males and 56 (37.3%) 
females. The mean duration of illness at the time of 
screening was 12.5 ± 9.7 days. Out of 150 patients, 110 
(73.3%) had positive COVID-19 PCR test results 
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whereas 40 (26.7%) were diagnosed on basis of HRCT 
findings. This is summarized in Table 1. Demographic 
characteristics and duration of illness at the time of 
screening with and without rash are summarized in 
Table 2. All patients with rash were males and had 
positive COVID PCR. Duration of illness at the time of 
screening in patients with rash was 8.6±3.4 days. 
Most of the patients did not show any specific or non-
specific dermatological manifestations related to 
COVID-19. Only 7 (4.7%) COVID-19 patients showed 
skin lesions. These included generalized bullous 
pemphigoid-like (1 patient), urticarial lesions (1 
patient), vesicular eruption/chickenpox-like (1 
patient), skin necrosis (1 patient), and maculopapular 
rash (3 patients). This is illustrated in Figure 1. Among 
the patients with maculopapular eruption, two had 
generalized morbilliform rash whereas one had 
erythema elevatum diutinum like lesions. This is 
shown in Table 3. Most of the patients with a rash had 
a generalized rash but the patient with skin necrosis 
had involvement of intergluteal cleft and buttocks 
only. The majority of patients with a rash had mild to 
moderate symptoms except the patient having skin 
necrosis who had severe disease and required HDU 
care. None of the patients with a rash had a history of 
any chronic dermatological disease. They had not 
taken any drug in the preceding 4 weeks of the 
eruption. The rash resolved spontaneously in the 
majority of patients (urticarial, vesicular, morbilliform 
and erythema elevatum diutinum like) without any 
specific treatment after resolution of fever.  However, 
the patient with bullous pemphigoid-like lesions 
(Figure 1-b) and generalized morbilliform rash (Figure 
1-d) required oral steroids. The patient with 
morbilliform rash (Figure 1-d) also had a prolonged 
rash of more than a month. The patient with skin 
necrosis had a prolonged course of severe illness with 
several days of HDU care but did not require 
mechanical ventilation. 
 
Figure 1: Dermatological manifestations of COVID-
19(*All pictures were taken with the consent of 
patients 
Table 1: Demographics & other characteristics of 
COVID-19 patients 
Total number of 
patients (N) 
150 
Mean age of 
patients 
51.9 ± 17.2 years 
Gender Male 94 (62.7%) 
Female 56 (37.3%) 
Covid-19 PCR Positive 110 (73.3%) 
Negative 40 (26.7%) 
 
Table 2: Demographics & other characteristics of 
COVID-19 patients (with and without rash) 
Characteristic Rash, n=7 No rash, n=143 




Male sex, n (%) 7 (100%) 87 (60.8%) 
Female sex, n (%) 0 (0%) 56 (39.2) 
PCR positive, n 
(%) 
7 (100%) 103 (72.0%) 
HRCT positive, n 
(%) 
0 (0%) 40 (28.0%) 
Duration of illness 
at screening, mean 
(SD) 
8.6 (3.4) days 12.1 (9.3) days 
 
Table 3: Dermatological patterns of COVID-19 




Urticarial lesions 1 
Vesicular eruption 1 
cutaneous necrosis 1 
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Discussion 
 
Viruses can cause characteristic exanthems which help 
the clinician make a diagnosis even before the 
laboratory confirmation. Contrary to the initial belief 
that COVID-19 does not involve skin but can cause 
different skin manifestations which are important to 
identify. However, none of the skin manifestations are 
specific or diagnostic for the disease. It is also not 
known what proportion of COVID‐19 infected patients 
develop cutaneous manifestations and the underlying 
mechanisms. However, doctors need to be vigilant 
about the possibility of COVID‐19 in a patient with a 
suggestive rash.8 
There is quite a variation in the prevalence of COVID-
19 associated skin manifestations around the globe. 
Data from an Italian study suggested 20% of patients 
had skin disease.3 In the United Kingdom, data from 
users of the COVID Symptom Study application 
suggested that 8.8% of 336,847 users, reported a skin 
rash.9 In a recent study from New York, the prevalence 
of mucocutaneous eruptions among a racially 
diversified cohort of hospitalized adults to be 
11.8%.10 Thus the data from the Western world is 
showing quite a high association of skin lesions with 
COVID-19. However, data from Asian countries like 
China is presenting a sharp contrast. Among 1099 
COVID-19 confirmed patients, only 0.2% presented 
with skin rash. In our study too, only 4.7% presented 
with the rash. Whether this is due to racial variation or 
differences in viral strains prevalent in different parts 
of the world, needs further research.11 
Recent publications have also made a very interesting 
observation of the relative absence of COVID-19 
related skin rashes in dark-skinned individuals. 
Indeed, Among 318 cases of COVID-19 related 
perniosis, very few patients of non-European descent 
were found. Also, there was a virtual absence of 
"Covid toes" among a large population of African-
American and Hispanic patients during the COVID-19 
outbreak in New York City.12 We, too, could not find a 
single patient of COVID toes in all of our screened 150 
patients. 
Similar observations have been made by a recent 
review. Cutaneous manifestations were found to be 
more common among Europeans and United States 
residents than among Asians, as was pseudo-chilblain, 
and the morphology of the skin lesions varied among 
continents. Pseudo-chilblains were the most common 
COVID-19 skin manifestation in Europe and the 
United States, but there was only 1 reported case from 
the Asian population.13 They also identified 
demographic differences in the prevalence and the 
morphology of the skin manifestations in COVID-19. 
Of the 1211 patients with COVID-19–associated skin 
manifestations, 39 (3.1%) patients were from Asian 
populations and 1172 (96.9%) patients were from 
Europe and the United States. This huge difference 
between the prevalence of cutaneous manifestations in 
Europeans and United States residents compared with 
Asians could be attributable to underreporting in 
Asian countries. However, in countries with a 
heterogeneous racial make-up, such as the United 
States, African-American, and Latino populations have 
been disproportionately affected. The implication of 
genetic factors in polymorphous cutaneous reactions 
in COVID-19 remains to be explored.  Our study also 
supports these observations. Despite an exhaustive 
inquiry from the 150 enrolled patients, we could only 
get 7 patients with skin manifestations. In another 
study by Dalal, et al. reported dermatological 
manifestations in 13 patients (12.7%) from North 
India.14 Whether this is the distinctive genetic makeup 
of the Pakistani population, or a different strain of 
virus is prevalent here, are the doors for future 
research. 
A systemic review tried to characterize the severity of 
COVID-19 disease with the type of cutaneous 
manifestations. It concluded that the mere presence of 
skin manifestations in COVID-19 patients is not an 
indicator for the disease severity, and it highly 
depends on the type of skin lesions. Chilblain-like and 
vascular lesions are the two ends of a spectrum in 
which from chilblain-like to vascular lesions, the 
severity of the disease increases, and the patient's 
prognosis worsens.15 Our study also supported these 
findings. The only patient with severe disease had 
vascular/ necrotic skin lesions.  
Cutaneous lesions occur most often in middle-aged 
individuals at the same time or after the systemic 
symptoms of COVID-19. In our study, we also found a 
mean age of 41 years in patients with rash. Urticaria-
like lesions commonly occurred at the same time as 
other symptoms. A maculopapular rash is the main 
reported skin involvement in COVID-19 patients and 
is associated with intermediate severity of the 
disease.15 We also found the majority of patients have 
a maculopapular rash (n=3). 
The pathogenesis of cutaneous manifestations in 
patients with COVID-19 is still evolving. 
Polymorphous cutaneous manifestations in patients 
with COVID-19 infection could potentially reflect a full 
spectrum of viral interactions with the skin, 
characterized by direct viral action in infected cells, 
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immune system hyperactivity, and 
hypercoagulability.16 
In summary, this study strongly supports the inclusion 
of skin rashes in the list of suspicious COVID‐19 
symptoms. Although they are less prevalent than 
fever, they are more specific and last longer, and can 
be easily spotted by patients. Thus increased 
awareness from the public and healthcare 
professionals regarding COVID‐19 skin changes will 





The skin manifestations of COVID-19 in Pakistan are 
much lower compared to reports and data from the 
western world. However, they are in accordance with 
the data reported from few Asian countries. 
Regardless of it, the type and association of skin 
lesions with COVID-19 disease severity appear to be 
universal. This difference in prevalence can be 
attributed to the racial differences and variety of viral 
strains predominant in different countries. Our study 
is the first of its kind in this country to throw light on 
these important facts.  However, further studies are 
required to dig further into the reality. 
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